Read More

FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape

FibroGen reveals Phase 1 results for FG-3246 for metastatic castration-resistant prostate cancer. Promising efficacy metrics and plans for enhanced therapeutic strategies signal potential advancements in treatment. Learn more about this groundbreaking development."

ABBV